Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.623
+0.228 (57.77%)
At close: Feb 27, 2026, 4:00 PM EST
0.580
-0.043 (-6.93%)
After-hours: Feb 27, 2026, 7:59 PM EST
Ensysce Biosciences Revenue
Ensysce Biosciences had revenue of $493.10K in the quarter ending September 30, 2025, a decrease of -85.58%. This brings the company's revenue in the last twelve months to $4.49M, up 1.51% year-over-year. In the year 2024, Ensysce Biosciences had annual revenue of $5.21M with 133.58% growth.
Revenue (ttm)
$4.49M
Revenue Growth
+1.51%
P/S Ratio
0.50
Revenue / Employee
$560,997
Employees
8
Market Cap
2.26M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionENSC News
- 1 day ago - Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review - Benzinga
- 3 days ago - Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value - Accesswire
- 5 days ago - Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events - Accesswire
- 4 weeks ago - Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain - Accesswire
- 5 weeks ago - Ensysce Biosciences Expands Global Opioid Patent Portfolio - Accesswire
- 7 weeks ago - Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection - Accesswire
- 7 weeks ago - Ensysce Biosciences, Inc. (ENSC) Shareholder/Analyst Call Prepared Remarks Transcript - Seeking Alpha
- 7 weeks ago - Ensysce Biosciences Issues Annual Shareholder Letter - Accesswire